Galectin Therapeutics Strengthens Leadership Team with Strategic Hires to Advance Programs in Cancer Immunotherapy and NASH CirrhosisGlobeNewsWire • 08/30/21
Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2021, and Provides Business UpdateGlobeNewsWire • 08/16/21
Galectin Therapeutics Stock Surges After Robust Data From Belapectin/Keytruda Combo In Melanoma, Head & Neck CancerBenzinga • 07/09/21
Galectin Therapeutics Announces Positive Top-Line Results from a Phase 1b Clinical Trial Extension of Belapectin in Combination with KEYTRUDA® in Advanced Metastatic Melanoma and Head and Neck CancerGlobeNewsWire • 07/09/21
Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2021, and Provides Business UpdateGlobeNewsWire • 05/17/21
Galectin Therapeutics: The Galectin Signature - Signed, Sealed, And About To Be DeliveredSeeking Alpha • 04/16/21
Galectin Therapeutics Stock Is Trading Higher After Belapectin-Pembrolizumab Combo Study Shows Enhanced Tumor ResponseBenzinga • 04/14/21
Journal for ImmunoTherapy of Cancer Publishes Phase 1 Clinical Research Showing Belapectin, Galectin Therapeutics' Galectin-3 Inhibitor, Enhances Tumor Response in Combination with Anti-PD-1 TherapyGlobeNewsWire • 04/13/21
Galectin Therapeutics Launches NAVIGATEnash.com, a Resource for Both Patients and Physicians about its Innovative NASH Cirrhosis StudyGlobeNewsWire • 04/06/21
Galectin Therapeutics Reports Fiscal 2020 Financial Results and Provides Business UpdateGlobeNewsWire • 03/31/21
Galectin Therapeutics, Inc. to Present at the 4th Annual Digital NASH Summit on December 17, 2020GlobeNewsWire • 12/11/20
Galectin Therapeutics Inc. Recaps Results of Annual Meeting of Stockholders PresentationGlobeNewsWire • 12/04/20
Galectin Therapeutics Provides Business Update And Reports Financial Results for the Quarter Ended September 30, 2020GlobeNewsWire • 11/09/20
Galectin Therapeutics Investor Conference Call and Webinar Taking Place TodayGlobeNewsWire • 09/29/20
Implied Volatility Surging for Galectin Therapeutics (GALT) Stock OptionsZacks Investment Research • 09/29/20
Galectin Therapeutics Announces Investor Conference Call and Webinar on September 29, 2020GlobeNewsWire • 09/22/20